Dimensional Fund Advisors LP Has $11.55 Million Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Dimensional Fund Advisors LP lowered its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 0.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,708,040 shares of the company’s stock after selling 9,739 shares during the period. Dimensional Fund Advisors LP’s holdings in Recursion Pharmaceuticals were worth $11,546,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Farther Finance Advisors LLC raised its holdings in Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after buying an additional 1,353 shares during the last quarter. Summit Investment Advisors Inc. raised its stake in shares of Recursion Pharmaceuticals by 7.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company’s stock valued at $176,000 after acquiring an additional 1,875 shares during the last quarter. Wedmont Private Capital lifted its holdings in shares of Recursion Pharmaceuticals by 10.6% during the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock worth $144,000 after purchasing an additional 2,000 shares during the period. Daiwa Securities Group Inc. grew its stake in shares of Recursion Pharmaceuticals by 28.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company’s stock worth $69,000 after purchasing an additional 2,235 shares during the last quarter. Finally, Green Alpha Advisors LLC increased its holdings in Recursion Pharmaceuticals by 3.6% in the fourth quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company’s stock valued at $454,000 after purchasing an additional 2,346 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock opened at $4.33 on Friday. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The business’s 50 day simple moving average is $5.53 and its 200 day simple moving average is $6.66. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -2.83 and a beta of 0.99.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. During the same quarter in the previous year, the company posted ($0.39) EPS. The firm’s revenue was up 7.2% compared to the same quarter last year. Sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on RXRX shares. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Leerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Morgan Stanley cut their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Finally, Needham & Company LLC dropped their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $7.60.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.